A Randomized, Open-label, Non-inferiority Study to Compare the Efficacy and Safety of Voglibose and Acarbose in Patients With Type 2 Diabetes Mellitus With Poor Control of Metformin
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Voglibose (Primary) ; Acarbose; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 14 Jul 2016 Status changed from recruiting to completed.
- 19 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.